P731 Stock Overview
Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Medexus Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$1.10 |
| 52 Week High | CA$2.30 |
| 52 Week Low | CA$0.78 |
| Beta | 1.85 |
| 1 Month Change | 6.80% |
| 3 Month Change | -34.52% |
| 1 Year Change | 20.88% |
| 3 Year Change | -77.64% |
| 5 Year Change | -57.50% |
| Change since IPO | -61.81% |
Recent News & Updates
Recent updates
Shareholder Returns
| P731 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 7.8% | 2.5% | 1.8% |
| 1Y | 20.9% | -27.7% | 2.2% |
Return vs Industry: P731 exceeded the German Pharmaceuticals industry which returned -27.7% over the past year.
Return vs Market: P731 exceeded the German Market which returned 2.2% over the past year.
Price Volatility
| P731 volatility | |
|---|---|
| P731 Average Weekly Movement | 11.7% |
| Pharmaceuticals Industry Average Movement | 6.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: P731's share price has been volatile over the past 3 months.
Volatility Over Time: P731's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 98 | Ken d'Entremont | www.medexus.com |
Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
Medexus Pharmaceuticals Inc. Fundamentals Summary
| P731 fundamental statistics | |
|---|---|
| Market cap | €27.52m |
| Earnings (TTM) | €5.49m |
| Revenue (TTM) | €108.13m |
5.3x
P/E Ratio0.3x
P/S RatioIs P731 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| P731 income statement (TTM) | |
|---|---|
| Revenue | US$115.73m |
| Cost of Revenue | US$48.91m |
| Gross Profit | US$66.81m |
| Other Expenses | US$60.93m |
| Earnings | US$5.88m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.24 |
| Gross Margin | 57.73% |
| Net Profit Margin | 5.08% |
| Debt/Equity Ratio | 174.9% |
How did P731 perform over the long term?
See historical performance and comparison